Evidence & regulatory context
- Mechanism
- No ChEMBL record under the code MCS-01 and no chemical name given in the source, so unresolvable by synonym search. No ClinicalTrials.gov record for MCS-01 itself; the 15 mast-cell-stabiliser hits were different chemical entities (cromolyn/ALZT-OP1a, ketotifen) and were deliberately NOT recorded as translation evidence for this molecule.
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundTopical, delivered by controlled release from specifically designed alginate bandagesApplied both before wounding and after wounding
Model: Excisional skin wounding in diabetic mice
Topical MCS-01 applied before or after wounding accelerated wound healing in diabetic mice to an extent comparable with systemic mast cell stabilisation, promoted classically activated macrophage polarisation, and modulated the wound mRNA and microRNA profile with upregulation of acute inflammation…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
